- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ATL introduces Apogee 800 Plus
Visitors to ATL's booth at next week's American Institute of Ultrasoundin Medicine meeting will get a glimpse of Apogee 800 Plus, theBothell, WA, company's newest platform. The scanner brings toa lower price point features found on ATL's premium HDI 3000
Visitors to ATL's booth at next week's American Institute of Ultrasoundin Medicine meeting will get a glimpse of Apogee 800 Plus, theBothell, WA, company's newest platform. The scanner brings toa lower price point features found on ATL's premium HDI 3000 scanner,according to Steve Anderson, director of value products.
Apogee 800 Plus builds on the Apogee 800 platform acquiredthrough ATL's purchase of Interspec. The new version featuresimage analysis packages first seen on HDI 3000, and has a new8-bit color processor and improved signal-to-noise ratio, thanksto improvements to Apogee 800's system receiver. The scanner willreplace ATL's Ultramark 4 in the mid-range segment (SCAN 2/14/96).Apogee 800 scanners in the field will be able to upgrade to thenew technology, Anderson said.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
